Search

• The Cervantes scale allows the quality of life of postmenopausal women to be measured. • Vulvovaginal atrophy impairs the quality of life of postmenopausal women. • Women treated with ospemifene have a better quality of life than those treated with local therapies. • These benefits of ospemifene are more evident in the domains of sexual and couple relations. To assess the correlation of different vulvovaginal atrophy therapeutic options with the quality of life of postmenopausal women. The CRETA study is a descriptive, observational, cross-sectional, multicenter study designed to measure, besides treatment satisfaction and adherence, the quality of life of postmenopausal women diagnosed with vulvovaginal atrophy in 29 hospitals and centers across Spain. The study enrolled postmenopausal women currently receiving treatment with vaginal moisturizers, local estrogen therapy or ospemifene. Clinical features and treatment perceptions were collected by self-report questionnaire and quality of life was evaluated using the Cervantes scale. Among the 752 women included, the ospemifene cohort showed a statistically significant lower global score (44.9 ± 21.7) on the Cervantes scale (and therefore, a better quality of life) than the cohorts treated with moisturizers (52.5 ± 21.6, p = 0.003) or local estrogen therapy (49.2 ± 23.8, p = 0.0473). In the analysis by domains, ospemifene-treated women showed statistically significant better scores in menopause & health and psychological status than moisturizers-treated women (p < 0.05). In the domains of sexuality and couple relations, the score for the quality of life of the ospemifene cohort was statistically significantly better than the scores in either of the cohorts treated with moisturizers (p < 0.001) or local estrogen therapy (p < 0.05). Postmenopausal women diagnosed with vulvovaginal atrophy and treated with ospemifene have better quality of life than women treated with vaginal moisturizers or local estrogen therapy. The improvement observed with ospemifene is more remarkable in those aspects related to sex life and couple relations. NCT04607707. [ABSTRACT FROM AUTHOR]

Background: It has been suggested that hormonal changes and environmental alterations during the climacteric period are important in the development of psychological symptoms. Objective: To evaluate the role of biological and psycho-social factors in the prevalence of climacteric symptoms. Design: Open, cross-sectional, observational and descriptive study. Material and methods: A total of 300 women between 40 and 59 years of age were evaluated using Greene scale for climacteric symptoms, Cooper questionnaire for psychosomatic symptoms of stress, Smilkstein family apgar for family dysfunction, Duke-UNC questionnaire for social support and Israel scale for vital events. All these tests have been previously validated in Spanish. Results: Postmenopausal women do not have higher prevalence of psychological symptoms, they only have more vasomotor symptoms. Premenopausal women with vasomotor symptoms have more psychological and somatic symptoms and stress, independently of the vital events, family dysfunction or poor social support. Vasomotor symptoms in the premenopause are associated with increased risk of anxiety (OR: 3.7, IC: 1.4–9.7; P<0.008), depression (OR: 8.1, IC: 2.5–26.4; P<0.0005), somatic symptoms (OR: 14.9, IC: 3.4–65.3; P<0.0003), sexual dysfunction (OR: 7.2, IC: 2.5–20.6; P<0.0002) and stress (OR: 7.5, IC: 3.5–15.9; P<0.0001). Negative vital events and family dysfunction increase in minor intensity the risk of anxiety, depression and stress. Conclusion: In conclusion, psychological symptoms are frequent in the premenopause and are associated to vasomotor symptoms. This observation links psychological symptoms with menopausal transition and might suggest an organic base in their origin. The negative psycho-social environment is a factor that favours the development of these symptoms. [Copyright &y& Elsevier]

Background: It has been suggested that psycho-social factors may be crucial in the development of climacteric symptoms. Material and methods: In order to evaluate the effect of psycho-social and biological factors on menopausal symptoms, Greene (climacterical symptoms), Cooper (psychosomatic symptoms of stress), Smilkstein (family dysfunction), Duke-UNC (social support) and Israel (life events) tests were passed to 300 Chilean women between 40 and 59 years of age. Data were evaluated with ANOVA, χ2 and logistic regression using the Epi-info package. Results: Perimenopausal women had a significant increase in stress and climacteric symptoms; however comparing with pre and postmenopausal women, tests for life events, family dysfunction or social support did not show any differences. A history of premenstrual syndrome was the main risk predictor f or climacteric symptoms (OR: 3.6, IC: 1.5–8.5; P<0.03), followed by perimenopausal state (OR: 2.9, IC: 1.4–6.0; P<0.001) and negative life events (OR: 2.3, IC: 1.0–5.3; P<0.05). The psycho-social factors were predictors for anxiety and depression; on the other hand, perimenopausal state was a risk factor for somatic and vasomotor symptoms. During premenopause, women with regular cycles and vasomotor symptoms have more psychological symptoms and stress. Conclusion: Climacteric symptoms that appear in the perimenopause are more intense in those women who have a biological predisposition such as premenstrual syndrome and are modulated by psycho-social factors. [Copyright &y& Elsevier]